{
  "LRCX": "Strong Q2 2026 Guidance and Market Upgrade, Increased 2027 Wafer Fab Equipment Forecast",
  "KYMR": "Positive trial data and drug approval prospects",
  "OFC": "Institutional investor interest and favorable market conditions",
  "AVPT": "Rising earnings estimates and potential for a 49.25% rally",
  "PRAX": "FDA breakthrough status for rare blood cancer therapy"
}